Brain-derived neurotrophic factor (BDNF) gene: No major impact on antidepressant treatment response

Katharina Domschke, Bruce Lawford, Gonzalo Laje, Klaus Berger, Ross Young, Phillip Morris, Jürgen Deckert, Volker Arolt, Francis J. McMahon, Bernhard T. Baune

Research output: Contribution to journalArticle

Abstract

The brain-derived neurotrophic factor (BDNF) has been suggested to play a pivotal role in the aetiology of affective disorders. In order to further clarify the impact of BDNF gene variation on major depression as well as antidepressant treatment response, association of three BDNF polymorphisms [rs7103411, Val66Met (rs6265) and rs7124442] with major depression and antidepressant treatment response was investigated in an overall sample of 268 German patients with major depression and 424 healthy controls. False discovery rate (FDR) was applied to control for multiple testing. Additionally, ten markers in BDNF were tested for association with citalopram outcome in the STARD sample. While BDNF was not associated with major depression as a categorical diagnosis, the BDNF rs7124442 TT genotype was significantly related to worse treatment outcome over 6 wk in major depression (p=0.01) particularly in anxious depression (p=0.003) in the German sample. However, BDNF rs7103411 and rs6265 similarly predicted worse treatment response over 6 wk in clinical subtypes of depression such as melancholic depression only (rs7103411: TT

Original languageEnglish (US)
Pages (from-to)93-101
Number of pages9
JournalInternational Journal of Neuropsychopharmacology
Volume13
Issue number1
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

    Fingerprint

Keywords

  • Antidepressant
  • BDNF
  • D
  • Depression
  • Neurotrophins
  • Pharmacogenetics
  • STAR
  • Treatment response

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Psychiatry and Mental health

Cite this